|
|
Article: Stressgen announces presentation of new Phase II HspE7 data on genital warts and anal dysplasia at HPV 2002.
- Article from:
- PR Newswire
- Article date:
- October 7, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The Company's Novel Immunotherapeutic, HspE7, Demonstrates Efficacy and Durable Response Over 24-Months
Stressgen Biotechnologies Corporation (TSX:SSB) will present data that the Company's lead product, HspE7, achieved complete responses of genital warts among a clinically significant percentage of patients for up to twenty-four months. New data were presented at the 20th International Papillomavirus Conference from three data sets of patients treated with HspE7, the Company's novel human papillomavirus (HPV)-specific immunotherapeutic. These data include new analysis of previously reported Phase II trial in genital warts; 24-month data from a retrospective study ...